Denali Therapeutics Inc.
Company Stats
- Market Cap
- $3.3B
- as of Sep 30, 2026
- Shares Outstanding
- 159.8M
- Free Float
- 89.5%
Income Statement
- Revenue
- $0
- Operating Income
- -$555.3M
- Net Income
- -$512.5M
- EBITDA
- -$544.2M
Cash Flow
- Free Cash Flow
- -$422.1M
- FCF Yield
- -12.8%
- Owner FCF Yield
- -15.8%
Balance Sheet
- Cash & Equivalents
- $205.3M
Returns & Capital
- SBC, 3Y Avg
- $103.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$422.1M | — |
| FY2024 | $0 | -$363.6M | — |
| FY2023 | $330.5M | -$370.9M | -112.2% |
| FY2022 | $105.1M | -$262.5M | -249.9% |
| FY2021 | $48.7M | -$219.9M | -451.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back